Mixed-grade papillary urothelial carcinoma with a minor high-grade component shows a significantly worse clinical outcome than low-grade papillary urothelial carcinoma.
William Mi, Chenxuan Zang, Jianping Zhao, Ashish M Kamat, Peng Wei, Donna E Hansel, Bogdan Czerniak, Charles C Guo
{"title":"Mixed-grade papillary urothelial carcinoma with a minor high-grade component shows a significantly worse clinical outcome than low-grade papillary urothelial carcinoma.","authors":"William Mi, Chenxuan Zang, Jianping Zhao, Ashish M Kamat, Peng Wei, Donna E Hansel, Bogdan Czerniak, Charles C Guo","doi":"10.1016/j.humpath.2025.105904","DOIUrl":null,"url":null,"abstract":"<p><p>Grade heterogeneity is common in papillary urothelial carcinoma (PUC) of the urinary bladder. Mixed-grade PUC is generally treated as high-grade if the high-grade component accounts for ≥5 % of the tumor. However, the clinical behavior of predominantly low-grade PUC with a minor high-grade (<5 %) component remains uncertain. We retrospectively searched our pathology files and identified 52 cases of non-invasive mixed-grade PUC (predominantly low-grade PUC with a minor high-grade (<5 %) component). These patients' clinical outcomes were compared with those of 2 other cohorts, 52 cases of pure low-grade PUC and 50 high-grade PUC. During follow-up, 27 patients with mixed-grade PUC developed cancer recurrence in an average of 25 months, and 12 patients experienced progression to high-grade PUC, including invasive UC in 3 patients, in an average of 17 months. For comparison, 35 patients with low-grade PUC experienced cancer recurrence in an average of 17 months, but only 1 (2 %) experienced progression to high-grade non-invasive PUC; 34 patients with high-grade PUC experienced recurrence in an average of 13 months, and 10 (20 %) experienced progression to invasive UC. There was no significant difference in cancer recurrence in the 3 cohorts; cancer grade and stage progression rates in patients with mixed-grade PUC were significantly higher than those in those with low-grade PUC, but stage progression rate in patients with mixed-grade PUC was significantly lower than that in high-grade PUC. In conclusion, patients with mixed-grade PUC had a significantly worse clinical outcome than those with pure low-grade PUC but a significantly better outcome than those with high-grade PUC. Our results suggest that mixed-grade PUC should be treated as a distinct category from low-grade PUC.</p>","PeriodicalId":13062,"journal":{"name":"Human pathology","volume":" ","pages":"105904"},"PeriodicalIF":2.6000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Human pathology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.humpath.2025.105904","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/8/7 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"PATHOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Grade heterogeneity is common in papillary urothelial carcinoma (PUC) of the urinary bladder. Mixed-grade PUC is generally treated as high-grade if the high-grade component accounts for ≥5 % of the tumor. However, the clinical behavior of predominantly low-grade PUC with a minor high-grade (<5 %) component remains uncertain. We retrospectively searched our pathology files and identified 52 cases of non-invasive mixed-grade PUC (predominantly low-grade PUC with a minor high-grade (<5 %) component). These patients' clinical outcomes were compared with those of 2 other cohorts, 52 cases of pure low-grade PUC and 50 high-grade PUC. During follow-up, 27 patients with mixed-grade PUC developed cancer recurrence in an average of 25 months, and 12 patients experienced progression to high-grade PUC, including invasive UC in 3 patients, in an average of 17 months. For comparison, 35 patients with low-grade PUC experienced cancer recurrence in an average of 17 months, but only 1 (2 %) experienced progression to high-grade non-invasive PUC; 34 patients with high-grade PUC experienced recurrence in an average of 13 months, and 10 (20 %) experienced progression to invasive UC. There was no significant difference in cancer recurrence in the 3 cohorts; cancer grade and stage progression rates in patients with mixed-grade PUC were significantly higher than those in those with low-grade PUC, but stage progression rate in patients with mixed-grade PUC was significantly lower than that in high-grade PUC. In conclusion, patients with mixed-grade PUC had a significantly worse clinical outcome than those with pure low-grade PUC but a significantly better outcome than those with high-grade PUC. Our results suggest that mixed-grade PUC should be treated as a distinct category from low-grade PUC.
期刊介绍:
Human Pathology is designed to bring information of clinicopathologic significance to human disease to the laboratory and clinical physician. It presents information drawn from morphologic and clinical laboratory studies with direct relevance to the understanding of human diseases. Papers published concern morphologic and clinicopathologic observations, reviews of diseases, analyses of problems in pathology, significant collections of case material and advances in concepts or techniques of value in the analysis and diagnosis of disease. Theoretical and experimental pathology and molecular biology pertinent to human disease are included. This critical journal is well illustrated with exceptional reproductions of photomicrographs and microscopic anatomy.